Alto Neuroscience, Inc. (NYSE:ANRO) Given Consensus Recommendation of “Buy” by Analysts

Alto Neuroscience, Inc. (NYSE:ANRO) has been assigned an average recommendation of “Buy” from the seven analysts that are covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year is $33.80.

ANRO has been the subject of a number of research reports. Wedbush assumed coverage on Alto Neuroscience in a report on Tuesday. They issued an “outperform” rating and a $29.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a research report on Wednesday, June 12th. Finally, Rodman & Renshaw started coverage on shares of Alto Neuroscience in a report on Friday, June 21st. They set a “buy” rating and a $43.00 price target on the stock.

Alto Neuroscience Price Performance

ANRO opened at $13.22 on Wednesday. Alto Neuroscience has a 1 year low of $7.91 and a 1 year high of $24.00. The firm’s fifty day moving average price is $11.77 and its two-hundred day moving average price is $13.08. The company has a quick ratio of 19.85, a current ratio of 19.85 and a debt-to-equity ratio of 0.04.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.60) EPS for the quarter, beating analysts’ consensus estimates of ($0.67) by $0.07. On average, equities analysts anticipate that Alto Neuroscience will post -2.64 EPS for the current year.

Insider Buying and Selling

In other news, insider Adam Savitz bought 12,069 shares of the stock in a transaction dated Tuesday, July 9th. The stock was purchased at an average cost of $12.60 per share, for a total transaction of $152,069.40. Following the transaction, the insider now owns 36,920 shares of the company’s stock, valued at $465,192. The purchase was disclosed in a filing with the SEC, which can be accessed through this link.

Hedge Funds Weigh In On Alto Neuroscience

A number of institutional investors and hedge funds have recently modified their holdings of the stock. University of Texas Texas AM Investment Managment Co. bought a new stake in shares of Alto Neuroscience during the first quarter worth $340,000. Jennison Associates LLC purchased a new stake in shares of Alto Neuroscience in the first quarter valued at approximately $7,039,000. Vanguard Group Inc. bought a new position in Alto Neuroscience in the first quarter worth approximately $8,233,000. Price T Rowe Associates Inc. MD purchased a new position in Alto Neuroscience during the 1st quarter worth $9,788,000. Finally, AWM Investment Company Inc. purchased a new position in Alto Neuroscience during the 1st quarter worth $4,592,000.

Alto Neuroscience Company Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.